Loading…
iSlim, LLC was warned for selling "Alfia Weight Loss Capsules," an unapproved new drug containing undeclared sibutramine (a withdrawn prescription ingredient linked to heart attack and stroke risk) in violation of sections 505(a) and 301(d) of the FD&C Act. The product was also misbranded under section 502, with marketing claims on the company's website asserting the capsules would curb appetite, increase energy, burn fat, and improve digestion—establishing drug intent without FDA approval. Laboratory analysis confirmed the presence of sibutramine, a pharmaceutical ingredient that had been removed from the U.S. market in 2010 due to safety concerns.